2020年09月21日EIDX（EIDX）今日股票行情是多少？

　　截止2020年09月21日22时02分EIDX（EIDX）最新价52.5600，涨跌额-0.1800，涨跌幅0.34%，昨收52.7400，今开52.3800，最高52.5600，最低50.6400，成交量8265手。

　　EIDX（EIDX）变动日期2020年05月05日，变动原因定期报告，已发行普通股3853.73万，已发行优先股--，公告日期2020年05月08日，已发行港股--，已发行国内股--，已发行海外股3853.73万，已发行其他股--。

　　EIDX（EIDX）2019年01月01日至2019年12月31日License revenue金额（USD）2669.10万，比率100%。

　　EIDX（EIDX）主要指标（币种：美元）：截止2020年03月31日EIDX（EIDX）市盈率（TTM）-65.2110496980041，市净率（MRQ）10.7070209421682，每股收益（TTM）-1.26957384008409，每股净资产4.5372097675343，每股股息（USD）--，周息率--%，收入总额--，收入总额同比--%，归母净利润-2282.40万，归母净利润同比-94.5282536435694%，毛利率--%，净利率--%，总股本3853.73万，总市值（USD）18.72亿。

　　报告日期2020年03月31日，年结日12-31，币种美元，EIDX（EIDX）收入--，收入增长--%，毛利--，毛利增长--%，归母净利润-2282.40万，归母净利润增长-94.53%，基本每股收益-0.6，稀释每股收益-0.6，销售毛利率--%，销售净利率--%。

　　报告日期2020年03月31日，年结日12-31，币种美元，EIDX（EIDX）净资产收益率-13.18%，总资产净利率-11.07%。

　　公司介绍： Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. It seeks to treat this well-defined family of diseases by targeting them at their collective source by stabilizing TTR. TTR is a protein that occurs naturally in the form of a tetramer (a molecular structure consisting of four identical subunits, or monomers) and performs multiple beneficial roles, including the transport of essential hormones and vitamins. Over 25 years of research have shown that ATTR is uniformly driven by destabilization of the TTR tetramer, stemming from either specific gene mutations or aging. TTR destabilization drives an irreversible dissociation of the tetramer into monomers, which subsequently aggregate and deposit predominantly in the heart and peripheral nervous system, leading to organ damage, loss of organ function, and eventual death if left untreated. There are currently no therapies approved by the U.S. Food and Drug Administration, or FDA, for the treatment of ATTR. It is building upon its significant mechanistic understanding of ATTR to develop a potentially disease-modifying treatment for this family of diseases.

　　本站数据均为参考数据，不具备市场交易依据。